Transcrocetin
drug drugOn this page
Also known as Ci 75100CI-75100CrocetinLEAF-4L6715Leaf-4l7520NSC-407300Trans-crocetinTranscrocetinaTranscrocetinateTranscrocetineTranscrocetinic acid
Summary
Transcrocetin (CHEMBL464792) is a phase-3 clinical-stage small-molecule nutraceutical; indicated across 7 conditions including glioblastoma and intermittent vascular claudication.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 7 conditions
- Clinical trials: 2
- Chemistry: 328.4 Da · C20H24O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL464792 |
| Name | Transcrocetin |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 5281232 |
| ChEBI | CHEBI:3918 |
| Molecular formula | C20H24O4 |
| Molecular weight | 328.4 |
| InChIKey | PANKHBYNKQNAHN-MQQNZMFNSA-N |
SMILES: C/C(=C\C=C\C=C(\C=C\C=C(\C(=O)O)/C)/C)/C=C/C=C(/C(=O)O)\C
IUPAC name: (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioic acid
ChEBI definition: A 20-carbon dicarboxylic acid which is a diterpenoid and natural carotenoid. Found in the crocus flower, it has been administered as an anti-fatigue dietary supplement.
Pharmacological roles (ChEBI): nutraceutical, antioxidant.
Other ChEBI roles (chemical / environmental): metabolite.
Also known as: Ci 75100, CI-75100, Crocetin, LEAF-4L6715, Leaf-4l7520, NSC-407300, Trans-crocetin, Transcrocetin, Transcrocetina, Transcrocetinate, Transcrocetine, Transcrocetinic acid
Parent form; salt/anhydrous children: CHEMBL3137335
Patent coverage: 1,683 distinct patent families (3,573 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| glioblastoma | 1 | MONDO:0018177 | EFO:0000519 |
| intermittent vascular claudication | 1 | MONDO:0005295 | EFO:0003876 |
| glioma | 1 | MONDO:0021042 | MONDO:0100342 |
| acute respiratory distress syndrome | 1 | MONDO:0006502 | EFO:1000637 |
| COVID-19 | 1 | MONDO:0100096 | MONDO:0100096 |
| cytokine release syndrome | 1 | MONDO:0600008 | |
| paraganglioma | 1 | MONDO:0000448 | EFO:1000453 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06640777 | PHASE3 | NOT_YET_RECRUITING | Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome |
| NCT04378920 | PHASE1/PHASE2 | COMPLETED | A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.